ישראל - עברית - Ministry of Health

שמעון שסטוביץ בעמ - אנטיפרספירנט

ישראל - עברית - Ministry of Health

שמן מרוקאי ישראל בעמ - עיצוב השיער

ישראל - עברית - Ministry of Health

שמן מרוקאי ישראל בעמ - עיצוב תלתלים

ישראל - עברית - Ministry of Health

teva israel ltd - paracetamol; pseudoephedrine as hydrochloride - קפסולות ממולאות נוזל - paracetamol 250 mg; pseudoephedrine as hydrochloride 30 mg - paracetamol

ישראל - עברית - Ministry of Health

teva israel ltd - chlorpheniramine maleate; paracetamol; pseudoephedrine as hydrochloride - קפסולות ממולאות נוזל - paracetamol 250 mg; pseudoephedrine as hydrochloride 30 mg; chlorpheniramine maleate 2 mg - paracetamol

ישראל - עברית - Ministry of Health

sanofi israel ltd - enoxaparin sodium - תמיסה להזרקה - enoxaparin sodium 100 mg/ml ml - enoxaparin - enoxaparin - enoxaparin sodium is an anti-coagulant. at dosesof 20 mg and 40 mg it is indicated for: - prophylactic treatment of thrombo-embolic disorders of venous origin and in particular in orthopedic surgery or in general surgery. - prevention of thrombus formation in the extra-corporeal circulation during hemodialysis. at dosege of 40 mg the indications are: - prophylactic treatment of deep vein thrombosis in patients who are bedridden due to an acute medial disorder: - heart failure (hyha class iii or iv) - acute respiratory failure - episode of acute infection or acute rheumatic disorder combined with at least one other venous thromboembolic risk factor. at high doses of 60, 80 ,100 mg clexan is indicated for: -treatment of deep vein thrombosis (dvt). - treatment of unstable angina and non-q-wave myocardial infaction administered concurrently with aspirin. - treatment of pulmonary embolism.treatment of acute st- segment elevation myocardial infarction, in combination with a thrombolytic agent in patients eligible o

ישראל - עברית - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - eptifibatide - תמיסה לאינפוזיה - eptifibatide 0.75 mg/ml - eptifibatide - eptifibatide - integrilin is indicated for the prevention of death and myocardial infarction in patients presenting with high risk unstable angina or non-q-wave myocardial infarction. integrilin is indicated in patients who are managed with standard medical therapies and/or with percutaneous coronary intervention. integrilin is also indicated as an adjunct to percutaneous transluminal coronary angioplasty (ptca) balloon angioplasty, directional atheretomy, transluminal extraction catheter atherectomy, rotational ablation angioplasty, or excimer laser angioplasty for the prevention of abrupt closure of the treated coronary vessel and related acute ischemic cardiac complications (death, myorardial infarction, need for urgent intervention). integrilin is intended for use with aspirin and heparin.

ישראל - עברית - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - eptifibatide - תמיסה להזרקה - eptifibatide 2 mg/ml - eptifibatide - eptifibatide - integrilin is indicated for the prevention of death and myocardial infarction in patients presenting with high risk unstable angina or non-q-wave myocardial infarction. integrilin is indicated in patients who are managed with standard medical therapies and/or with percutaneous coronary intervention. integrilin is also indicated as an adjunct to percutaneous transluminal coronary angioplasty (ptca) balloon angioplasty, directional atheretomy, transluminal extraction catheter atherectomy, rotational ablation angioplasty, or excimer laser angioplasty for the prevention of abrupt closure of the treated coronary vessel and related acute ischemic cardiac complications (death, myorardial infarction, need for urgent intervention). integrilin is intended for use with aspirin and heparin.

ישראל - עברית - Ministry of Health

teva pharmaceutical indust.ltd - eptifibatide 2 mg/ml - solution for injection - eptifibatide - eptifibatide teva is indicated for the prevention of death and myocardial infarction in patients presenting with high risk unstable angina or non-q-wave myocardial infarction. eptifibatide is indicated in patients who are managed with standard medical therapies and/or with percutaneous coronary intervention. eptifibatide is also indicated as an adjunct to percutaneous transluminal coronary angioplasty (ptca) balloon angioplasty directional atheretomy transluminal extraction catheter atherectomy rotational ablation angioplasty or excimer laser angioplasty for the prevention of abrupt closure of the treated coronary vessel and related acute ischemic cardiac complications (death myorardial infarction need for urgent intervention). eptifibatide is intended for use with aspirin and heparin.

ישראל - עברית - Ministry of Health

novartis israel ltd - hydrochlorothiazide; valsartan - טבליות מצופות פילם - valsartan 80 mg; hydrochlorothiazide 12.5 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension for patients in whom combination therapy is appropriate.